DJIA 17,828.24 0.49 0.00%
NASDAQ 4,791.63 4.31 0.09%
S&P 500 2,067.56 -5.27 -0.25%
market minute promo


company name or ticker
Company Photos
(Click to zoom)

Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't

Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About

Gilead Sciences Inc. Breathes a Sigh of Relief -- Hepatitis C Patients, Not So Much

Merck's new hepatitis C combination doesn't work all that well for short durations. Gilead Sciences' Harvoni is safe for now.

Blackhill Bets Almost Half of Portfolio on Williams-Sonoma

Weekly Pharmaceuticals Notes: Pfizer, Bristol-Myers, Squibb, Merck And Roche

Insider Trading Alert - PX, CDW And BMY Traded By Insiders

3 Drugs That Make Gilead Sciences' Harvoni Look Cheap

Cancer drugs from Bristol-Myers Squibb, Novartis, and Roche come with higher price tags than Gilead Sciences hepatitis C drug Harvoni.

A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio

InsiderInsights.com Daily Round Up 11/7/14: AKS, ENH, SCCO, ERII

Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog

Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog

Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig

Pharmacyclics third-quarter results showed impressive sales growth for Imbruvica, a drug that competes against Gilead's Zydelig.
See More Articles...